의료진 > 진료과ㆍ의료진 > 진료ㆍ예약 | 가톨릭관동대학교 국제성모병원

가톨릭관동대학교 국제성모병원

관심의료진관심의료진 등록

장현 교수 과장

진료분야 진행/전이/재발 종양의 항암약물치료(폐암, 위암, 대장암, 유방암, 두경부암, 비뇨기암, 췌장암, 신장암), 완화의료, 신약임상연구

진료예약

진료시간표는 사정에 따라 변경될 수 있습니다.

진료

모바일로 확인하실 경우 표를 좌우로 움직여 내용을 확인 하실 수 있습니다.

6월
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30
오전
오후

모바일로 확인하실 경우 표를 좌우로 움직여 내용을 확인 하실 수 있습니다.

7월
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31
오전
오후


마르퀴즈 후즈 후 평생공로상(Albert Nelson Marquis Lifetime Achievement Award) 수상

경력
  • 현재 가톨릭관동대 국제성모병원 교수
  • 2022 ~ 현재 가톨릭관동대학교 의과대학 교수
  • 2022 ~ 현재 가톨릭관동대 국제성모병원 종양혈액내과장
  • 2014 ~ 2022 가톨릭관동대 국제성모병원 종양내과 과장
  • 2017 ~ 2022 가톨릭관동대학교 의과대학 부교수
  • 2017 ~ 2021 가톨릭관동대 국제성모병원 맞춤형암치유병원 부원장
  • 2014 ~ 2017 가톨릭관동대학교 의과대학 조교수
  • 2012 ~ 2014 분당서울대병원 혈액종양내과 진료교수
  • 2011 ~ 2011 연세대 세브란스병원 종양내과 임상연구 조교수
  • 2010 ~ 2010 연세대 세브란스병원 종양내과 전임의
  • 2007 ~ 2010 해군 내과 과장(군의관)
  • 2002 ~ 2007 연세대 세브란스병원 내과 전공의
학력
  • 2010 ~ 2015 연세대학교 의과대학원 의학박사
  • 2004 ~ 2006 연세대학교 의과대학원 의학석사
  • 1996 ~ 2002 연세대학교 의과대학 의학사
학회활동
  • 정보의학인증의 (Certified physician in biomedical informatics)
  • 대한항암요법연구회 회원
  • 대한종양내과학회 회원
  • 대한암학회 회원
  • 대한내과학회 회원
수상
  • 2010 연세대학교 대학원 우수업적 장학금
  • 2021 대한종양내과학회 머크학술상 최우수상 수상
  • 2019 Abstract Award of 2019 ASCO Breakthrough Summit, Bangkok, Thailand 수상
  • 2017 마르퀴즈 후즈 후 평생공로상(Albert Nelson Marquis Lifetime Achievement Award) 수상
  • 2016 세계 3대 인명사전 마르퀴즈 후즈 후(Marquis Who`s Who in the World) 등재
  • 2015 AstraZeneca-KHIDI Oncology research program 연구자 선정
  • 2013 분당서울대병원 일반연구자 사업 연구비 수혜
  • 2013 연세대학교 대학원 우수업적 장학금
  • 2013 교육과학기술부 일반연구자지원사업 기본연구
  • 2012 분당서울대학교 병원 육성연구과제 연구비 수혜
  • 2012 임상시험전문인력 인증(QPI)
  • 2011 연세대학교 대학원 우수업적 장학금
  • 2011 연세대학교 내과학교실 학술연구비 수혜
  • 2011 보건산업 진흥원 임상 의과학자 양성과정
  • 2010 연세대학교 대학원 우수업적 장학금
  • 2010 한국암학술재단 암연구 장학사업 장학생
더보기
논문
  • Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model, 2023.01, Investigative and clinical urology.
  • Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12, 2021.07, Cancer research and treatment
  • 2020 Korean guidelines for the management of metastatic prostate cancer, 2021.05, The Korean journal of internal medicine
  • Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12, 2020.12, Journal of Cancer Research and Clinical Oncology
  • Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma, 2020.07, Cancers (Basel)
  • Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer, 2019.10, EMBO molecular medicine
  • Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis:, 2019.09, Cancer medicine
  • Prognostic significance of metabolic parameters measured by 18F-FDG PET/CT in limited-stage small-cell lung carcinoma., 2019.05, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Epidermal Growth Factor Receptor Gene Amplification Predicts Worse Outcome in Patients With Surgically Resected Nonadenocarcinoma Lung Cance, 2019.01, Clinical Lung Cancer
  • Pancreatic-cancer-cell-derived trefoil factor 2 impairs maturation and migration of human monocyte-derived dendritic cells in vitro, 2018.10, Animal Cells and Systems
  • Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma., 2018.05, CANCER RESEARCH AND TREATMENT
  • Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients, 2017.12, SUPPORTIVE CARE IN CANCER
  • Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy., 2017.10, MEDICINE
  • Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer, 2017.09, Lung cancer
  • Establishment of a conditional transgenic mouse model recapitulating EML4-ALK-positive human non-small cell lung cancer, 2017.03, Journal of Thoracic Oncology
  • EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells, 2017.01, Yonsei Medical Journal
  • EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy, 2016.08, Oncotargets and Therapy
  • Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative., 2016.03, ONCOTARGET
  • Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer., 2016.01, GASTRIC CANCER
  • p21-Activated Kinase4(PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines., 2015.07, CANCER RESEARCH AND TREATMENT
  • Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors, 2014.10, Thoracic Cancer
  • Salvage treatment with low-dose weekly paclitaxel in elderly or poor performance status patients with metastatic urothelial carcinoma., 2014.07, Tumori
  • A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer, 2014.04, CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Sorafenib-Induced Tumor Response in a Patient With Metastatic Epithelioid Angiomyolipoma, 2014.04, JOURNAL OF CLINICAL ONCOLOGY
  • The early discontinuation of palliative chemotherapy in older patients with cancer, 2014.03, SUPPORTIVE CARE IN CANCER
  • Novel EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry, 2014.03, LUNG CANCER
  • Who should be admitted to the intensive care unit? The outcome of intensive care unit admission in stage IIIB-IV lung cancer patients, 2014.03, MEDICAL ONCOLOGY
  • Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer, 2014.02, WORLD JOURNAL OF SURGICAL ONCOLOGY
  • Prevalence and Risk Factors for Iron Deficiency Anemia in the Korean Population: Results of the Fifth Korea National Health and Nutrition Examination Survey, 2014.02, JOURNAL OF KOREAN MEDICAL SCIENCE
  • Multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes., 2013.12, ANNALS OF ONCOLOGY
  • Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells., 2013.03, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
  • Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer., 2012.08, Anticancer Res.
  • Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells., 2011.01, Breast Cancer Res Treat.
  • Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance., 2010.08, Cancer Chemother Pharmacol.
  • Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators., 2010.03, Journal of Cancer Research and Clinical Oncology
  • Adenosine triphosphate-based chemotherapy response assay(ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer., 2009.10, Anticancer Research.
  • High dose chemotherapy and autologous stem cell transplantation in non-Hodgkin's lymphoma: an eight-year experience., 2006.10, Yonsei Med J.

    선택하신 의료진
    전화예약 또는 첫 진료 고객 상담으로 예약을 진행하고 있습니다.

    닫기